The Parsemus Foundation and its social venture subsidiary Revolution Contraceptives, LLC have partnered with NEXT Life Sciences to continue development of the Vasalgel male contraceptive. NEXT Life Sciences announced launch of Plan A birth control for men, using the Vasalgel technology.
PROJECT
Vasalgel Male
Contraceptive
HUMAN HEALTH
PROJECT
Vasalgel Male
Contraceptive
HUMAN HEALTH
Plan A male contraceptive
A new home
After a decade of research on Vasalgel, the Parsemus Foundation determined that the reversible, long-lasting contraceptive for men was ready to advance to the next level. The search began for an organization with the resources needed to lead the project to the marketplace, including clinical trials and regulatory review. The Parsemus Foundation selected NEXT Life Sciences, Inc. as that partner. NEXT Life Sciences’ mission is to develop and distribute medical technology that empowers people to choose when and whether to have a child.
NEXT Life Sciences announced its launch of the product called Plan A, using the Vasalgel technology for male contraception. The NEXT team expects Plan A to be available to the public in 2026.
For more information, see the NEXT Life Sciences and Plan A websites.
Related posts
How to stay connected
Sign up for updates on Vasalgel from NEXT Life Sciences.
Visit the NEXT Life Sciences Plan A website to get more information on Vasalgel.
What people are saying
Tell us what
you think.
Any suggestions to make it better?